AXIM - AXIM Biotechnologies, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1499
-0.0101 (-6.31%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1600
Open0.1501
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1400 - 0.1850
52 Week Range0.1000 - 1.6800
Volume304,178
Avg. Volume153,616
Market Cap9.449M
Beta (5Y Monthly)-2.93
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateApr 30, 2018 - May 06, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound
    GlobeNewswire

    AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound

    SAN DIEGO, March 24, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
    PR Newswire

    Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

    Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech" or "AXIM") has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. ("Sapphire").

  • The Week In Cannabis: Marijuana Stocks Outperform The S&P During Coronavirus Pandemic
    Benzinga

    The Week In Cannabis: Marijuana Stocks Outperform The S&P During Coronavirus Pandemic

    The coronavirus pandemic has affected the cannabis and psychedelics industries in many different ways -- some more negative than others.While we continue to see massive layoffs, management shakeups and event cancellations across the board, businesses are struggling to adapt to their new situations, offering delivery services, free access to virtual platforms and more. Many cities have declared quarantines, but deemed dispensaries as essential services, allowing them to continue to operate under certain guidelines and limitations."The COVID-19 virus has affected everyone's normal way of doing business. Cannabis companies are more accustomed than most to pivot and pivot hard when things change overnight," Green Market Report CEO Debra Borchardt told Benzinga."Delivery services have increased, curbside options have begun and many dispensaries have vowed to remain open at some level. Sales are robust at most as the stress of this situation has caused many consumers to need cannabis to reduce anxiety or at least make the quarantine period a little more tolerable."If you want to get this news recap in your email inbox every week, please subscribe to https://tinyletter.com/javierhasseKhiron Life Sciences Corp (OTC: KHRNF) announced good news from Colombia: it has received an authorization to start manufacturing cannabis-containing medicines, becoming the first company operating in the country to do so. Khiron said it expects to start filling prescriptions in the next few days.Cannabis ETFs were once again in the red. Over the last five trading days:The ETFMG Alternative Harvest ETF (NYSE: MJ) lost 5.9%.The AdvisorShares Pure Cannabis ETF (NYSE: YOLO) tumbled 5.6%.The Cannabis ETF (NYSE: THCX) dropped 0.4%.The Amplify Seymour Cannabis ETF (NYSE: CNBS) shed 3.2%.The SPDR S&P 500 ETF Trust (NYSE: SPY) closed the period down 15%.Back in the U.S., Massachusetts witnessed an uptick in cannabis prices driven by high demand in a limited supply context.We also saw a report that Cronos Group, Inc. (NASDAQ: CRON) is under SEC investigation after failing to file its fiscal 2019 financial statements twice.Also check out our new bi-monthly psychedelics news roundup, "Psyched," and news in Spanish on El Planteo.In the psychedelics world, Mindbloom said it has made its ketamine treatment available to New Yorkers in a fully remote format. More about how this works here.More Cannabis News From The Week Cantor Fitzgerald analyst Pablo Zuanic slashed the sell-side firm's Tilray Inc (NASDAQ: TLRY) price target in the wake of Canada-based company's pricing of a .4-million equity offering. Zuanic maintained a Neutral rating on Tilray and lowered the price target from $17.50 to $4.90.While Zuanic said he understands the need to raise funds, he was surprised Tilray would choose "the worst of times" to price the offering. The analyst weighed whether other cannabis companies will follow suit, and said that in the case of Aurora Cannabis (NYSE: ACB), the company is likely to rely on cost cuts, positive EBITDA and lower capex to get by."The boom and bust in Canadian cannabis stocks has scared away a good number of investors," Zuanic said, adding that Cantor is comfortable with underlying trends.Zuanic also maintained an Overweight rating on CV Sciences Inc (OTC: CVSI), but reduced his price target from $1.60 to 80 cents, following fourth-quarter results that fell short of expectations.CanaFarma Hemp Products signed a lease for 100 acres of farmland in Cato, New York, almost doubling the acreage the company had in 2019.In 2019, CanaFarma Hemp worked a 55-acre farm in New York and delivered 128,000 pounds of hemp biomass, achieving a yield of over 2,300 pounds per acre. That's 50% better than the average farm yield, which CanaFarma said is in the range of 1,500 pounds per acre.Cannabis distribution company SparqOne entered distribution agreements with cannabis brands Kushy Punch, Church, Mindset Organics, Branded and Smoakland."The SparqOne team is excited to be joining forces with such renowned cannabis brands and we are looking forward to bolstering the product lineup for our dispensary partners. We have a strong relationship with almost every dispensary in the state and we can attribute that to our customer service, highly advanced logistics and dedication to next-day delivery no matter how large the order or how far the dispensary," said Andrew Dorsett, general manager of SparqOne.AXIM Biotechnologies (OTC: AXIM), an international health care solutions company targeting oncological and cannabinoid research, announced the full acquisition of leading oncology R&D company Sapphire Biotech, Inc. As part of the deal, AXIM has acquired 100% of the capital stock of Sapphire and will operate the company as a wholly owned subsidiary led by CEO Catalina Valencia."Through this acquisition, AXIM expands its historically cannabinoid-based research to include a focus in oncology," said John W. Huemoeller II, CEO of AXIM Biotech. "Sapphire was attractive to us because of its renowned research team, impressive discoveries in the field of oncology, and impressive IP portfolio."Nabis Holdings Inc. (OTC: NABIF)(CSE: NAB) cancelled an agreement to acquire Desert's Finest dispensary in California."Given the downturn in the cannabis industry, capital markets are no longer helping fuel growth, resulting in the company narrowing their focus on acquiring assets that fit into our vertically integrated strategy," Nabis CEO Shay Shnet said in a statement. "Although the Desert's Finest acquisition was a great opportunity for us to enter the California cannabis market, acquiring a standalone dispensary no longer fits into our strategic plan."HEXO Corp. (NYSE: HEXO) said it has not met the deadline for filing its interim financial statements for its fiscal second quarter because of several unexpected circumstances, such as having a huge impairment loss in the quarter, with the final amount still to be calculated. Until the filings are submitted, Hexo will hold a blackout on trading by directors, officers and remaining insiders of the company.It has revealed some financial results for the quarter, including net revenue of $17 million, compared to $14.5 million in the previous quarter, and gross revenue of $23.8 million versus $19.3 million in the first quarter.Canopy Growth (NYSE: CGC) decided to temporarily stop operating all corporate-owned Tokyo Smoke and Tweed retail stores across Canada, respecting the advice provided by various health bodies concerning the COVID-19 outbreak."We have a responsibility to our employees, their families and our communities to do our part to "flatten the curve" by limiting social interactions. For us, that means shifting our focus from retail to e-commerce," said Canopy Growth CEO David Klein.Medicine Man Technologies Inc. (OTC: MDCL) appointed Nirup Krishnamurthy to the role of chief integration and information officer.Cannabis industry veteran Joe Hodas joined Wana Brands as chief marketing officer.Aleafia Health Inc. (OTC: ALEAF) reported a surge in fiscal year 2019 and fourth-quarter revenue. The Canadian company said that its fourth-quarter net revenue of $6 million represents a 22% quarter-over-quarter increase.For full fiscal 2019, Aleafia posted net revenue of $16.4 million, 391% higher than in fiscal 2018. The revenue rise was mainly driven by an increase in net cannabis revenue of $11 million and $2 million in clinic revenue, the company said.For the quarter, Aleafia disclosed a net loss of $9.8 million versus net income of $1.9 million in the prior quarter. The company also reached its first quarterly positive adjusted EBITDA of $200,000 versus a loss of $2.5 million in the previous quarter.Crescita Therapeutics Inc. (TSX: CTX) (OTC: CRRTF) disclosed its fourth quarter and fiscal 2019 financial results. The Mississauga-based company reported annual record revenue of CA$22.34 million ($15.52 million), up by 34.3% from the previous year. Quarterly revenue of CA$3.82 million was down by 38.4% from the same period in the prior year.Sproutways, an open marketplace for cannabis genetics, is teaming up with greenhouse operator Wave Rider Nursery and Santa Cruz Naturals. The agreement between Sproutways, Monterey Bay-based Wave Rider and the Santa Cruz County dispensary aims to provide streamlined access to METRC-compliant seeds, clones and flowers.Greenhouse operator Village Farms International (NASDAQ: VFF) (TSX: VFF) received an infusion of CA$10 million ($6.92 million) in capital thanks to a deal with Beacon Securities Ltd. The deal, announced Thursday, calls for the purchase of 3,125,000 common shares in Village Farms at CA$3.20 per share.Green Growth Brands (CSE: GGB) (OTC: GGBXF) announced that Peter Horvath resigned as CEO and as a member of the board of directors. Horvath had served as CEO of Green Growth since early 2019 and joined the board in mid-2018.COO Randy Whitaker was named as Green Growth's interim CEO.Harvest One Cannabis (TSE: HVT) (OTC: HRVOF) appointed CCO Andy Bayfield to the position of interim CEO, effective immediately. Bayfield will also be appointed to the company's board of directors. Frank Holler was also appointed as executive chairman. The company has accepted the resignation of former CEO Grant Froese from his executive position and from the board of directors.As COVID-19 spreads around the globe, we're seeing an increasing number of hospitals and clinics that are not adequately prepared for the surge in patients looking to see a doctor. During this crisis, Heally is making its digital patient platform available to any physician's office to use at no charge.For patients, it costs $39.Top Stories Of The Week Check out the top stories on Benzinga Cannabis this week: * Why Restructuring Efforts Don't Necessarily Signal The End Of A Cannabis Company's Downturn * Should I Use Marijuana During The Quarantine? * Cannabis Inhalers: The Next Big Thing For Asthma And Cancer Pain Relief? * How The Coronavirus Is Impacting The Cannabis Industry * Coronavirus, Weed And Nicotine: Are Smokers And Vapers Facing Greater Risks? * Women's History Month: The Women of Cannabis Advocacy And Legalization * How To End Cannabis Stigma Forever * Is Smoking Marijuana Dangerous? A Scientific Review Of Cannabis Smoking And Lung Cancer - Compared To Tobacco * New Cannabis Products: A Broad Spectrum Line, A CBD Oral Applicator, And (Of Course) CBD/CBG Hand Sanitizer * New Cannabis Products: MyCHELLE And Prima's Skincare, Cut&Dry's Flower * Amsterdam-Based Dutch Passion Announces High-THC Auto Strain, Unfortunately Timed Italy Venture * How Social Distancing Is Driving Cannabis Demand * BofA On Organigram, Tilray, Aphria's Cash, Demand Trends * 3 Ways To Share Cannabis Without Transmitting The CoronavirusCheck out these and many other cannabis stories on Benzinga.com/cannabisLead image by Ilona Szentivanyi. Copyright: Benzinga.See more from Benzinga * The Week In Cannabis: Coronavirus Drop, Major Financing Agreements, Psychedelics Getting Hot * Canopy Growth's Storz & Bickel Bypasses Apple's Vaping App Ban With New Web App * Longtime Medicine Man Employee Launches Cannabis Consultancy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
    GlobeNewswire

    AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

    NEW YORK, March 18, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • AXIM® Biotechnologies Nutraceutical Division Announces Launch of CBD-Based Gum for Professional and Amateur Golfers
    GlobeNewswire

    AXIM® Biotechnologies Nutraceutical Division Announces Launch of CBD-Based Gum for Professional and Amateur Golfers

    NEW YORK, Feb. 26, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
    GlobeNewswire

    Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol

    NEW YORK, Feb. 18, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • AXIM® Biotechnologies Nutraceutical Division Announces Launch of Cannabinoid-Based Workout Gum and Other Upcoming Product Launches
    GlobeNewswire

    AXIM® Biotechnologies Nutraceutical Division Announces Launch of Cannabinoid-Based Workout Gum and Other Upcoming Product Launches

    NEW YORK, Feb. 12, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs Sponsored Research Agreement with Arizona State University to Develop Metastatic Cancer Inhibitor
    GlobeNewswire

    AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs Sponsored Research Agreement with Arizona State University to Develop Metastatic Cancer Inhibitor

    SAN DIEGO, Feb. 10, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology
    GlobeNewswire

    AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology

    SAN DIEGO, Jan. 22, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting.

  • Benzinga

    The Details Of The Acquisition Of Sapphire Biotech By Medical Marijuana Inc.'s AXIM Biotech

    Medical Marijuana, Inc. (OTC: MJNA) announced Thursday that its investment company, AXIM Biotechnologies Inc. (OTC: AXIM), has entered a binding term sheet to acquire Sapphire Biotech, Inc., oncology research and development company. AXIM Biotechnologies and Sapphire plan to sign definitive documents for the transaction before the end of February. Sapphire is working on the development of therapeutics for preventing cancer growth and metastasis.

  • Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
    PR Newswire

    Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.

    Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech" or "AXIM") has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech, Inc. ("Sapphire") as a wholly-owned subsidiary.

  • AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
    GlobeNewswire

    AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.

    SAN DIEGO, Jan. 08, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development,.

  • Benzinga

    The Week In Cannabis: A Federal Legalization Bill, Earnings Reports And A Tax Hike In California

    For the first time ever, a congressional committee in the U.S. has voted on a cannabis legalization bill. The law in question, the Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2019, passed the House Judiciary Committee Wednesday in a 24-10 vote.

  • New Notice of U.S. Patent Allowance Granted to Axim® Biotechnologies for Suppository Formulations Comprising Cannabinoids
    GlobeNewswire

    New Notice of U.S. Patent Allowance Granted to Axim® Biotechnologies for Suppository Formulations Comprising Cannabinoids

    NEW YORK, Nov. 21, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.

  • Benzinga

    The Week In Cannabis: Hexo Postpones Q4 Report, Rapinoe Teams With CBD Brand, Sanders Unveils Legalization Plan

    Business, finance and policy leaders from around the globe convened this week in Chicago for the Benzinga Cannabis Capital Conference to hear from the main voices in the space, from Bruce Linton, executive chairman of Gage Cannabis, and Jessica Billingsley, CEO of Akerna Corp (NASDAQ: KERN), to Tim Seymour, Jon Najarian and Jim Belushi. The corporate world continued to suffer, as more big public companies continued to put out bad news, including HEXO Corp (NYSE: HEXO) postponing its fourth-quarter report and announcing considerable layoffs — and at the same time launching a $70 million private placement.

  • AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
    GlobeNewswire

    AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference

    NEW YORK, Oct. 22, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development,.

  • AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting
    GlobeNewswire

    AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting

    (“AXIM® Biotech,” “AXIM” or “the Company”) (AXIM), a world leader in cannabinoid research and development, today announced that it has signed a cultivation agreement with a top hemp farm in North Carolina to establish the Company’s first domestic industrial hemp source.

  • Benzinga

    The Week In Cannabis: Big Pharma Makes Moves, Diddy & Wahlberg Go After CBD, Medicine Man Continues M&A Spree

    This week, we saw Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) make a big move in the cannabis industry, through a distribution deal between its subsidiary Salomon, Levin, Elstein, and InterCure Ltd ...

  • PR Newswire

    Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies

    SAN DIEGO , Sept. 12, 2019 /PRNewswire/ --  Medical Marijuana, Inc . (OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...

  • Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
    GlobeNewswire

    Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies

    (“AXIM® Biotech,” “AXIM” or “the Company”) (AXIM), a world leader in cannabinoid research and development, announced today that its contract manufacturer Eurofins Amatsigroup has begun manufacturing AXIM’s patented cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), for use in the Company’s upcoming clinical studies on cannabis as a treatment for chemotherapy related symptoms. According to the Center of Disease Control and Prevention (CDC), about 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic each year with an average cost of $100,000 per patient per year. Chemotherapy has been proven to be an effective treatment to kill cancer cells but in the process causes damage to other cells and tissues in the body.

  • New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids
    GlobeNewswire

    New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids

    NEW YORK, Aug. 08, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today.

  • Benzinga

    Cannabinoid R&D Updates: Medical Marijuana Inc And Axim Biotech

    Medical Marijuana, Inc. (OTC: MJNA) subsidiary Kannaway has entered a strategic partnership with Endocanna Health, a research and development biotechnology company specializing in endocannabinoid DNA testing and personalization. Under the terms of the agreement, Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits and license its proprietary DNA technology to Kannaway.

  • AXIM® Biotechnologies Launches AXIM® Wellness Division Focused on Cannabinoid-Based Nutraceutical Products and Announces New Product Pipeline
    GlobeNewswire

    AXIM® Biotechnologies Launches AXIM® Wellness Division Focused on Cannabinoid-Based Nutraceutical Products and Announces New Product Pipeline

    AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has launched its AXIM® Wellness division that will be focused on bringing consumers premium cannabinoid-based nutraceutical products. AXIM® Wellness division will address the high demand for cannabinoid-based solutions worldwide through a series of patented nutraceutical products.

  • AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months
    GlobeNewswire

    AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months

    NEW YORK, July 11, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.

  • AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division
    GlobeNewswire

    AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division

    NEW YORK, July 09, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.